PE 22-28 and the speed of neuroplasticity vs SSRIs
Posted by restlessemma in Research & News - 7 points, 4 comments.
I was digging through some recent papers on TREK-1 channel blockade and keep coming back to PE 22-28. The preclinical data on how it promotes synaptogenesis and neurogenesis is pretty wild. Most of the antidepressant research we see is focused on SSRIs, which can take weeks or even months to show any real change in mood. The idea of a peptide that could potentially trigger neuroplasticity much faster is massive, imo.
It is still just preclinical stuff, so I am not saying we should all be running it, but the mechanism is interesting. Instead of just tweaking serotonin levels, it is actually targeting the structural side of things through that spadin-derived pathway. I am curious if this could eventually be a way to bypass the lag time people experience with traditional meds.
I wonder if the short half-life is going to be a massive hurdle for actual therapeutic use, or if it makes it safer for fine-tuning neuroplasticity without long-term accumulation... Has anyone else been following the TREK-1 research lately? It feels like a much more direct way to look at brain repair than what we are currently doing.
Comments
- tracker_jade: I haven’t tried PE 22‑28 myself, but I’ve been watching the TREK‑1 papers pop up in my feeds. Anecdotally, the idea of a peptide that could jump‑start synaptogenesis faster than the weeks‑long SSRI ramp‑up is intriguing, especially for someone who’s seen patients struggle with that lag. The short half‑life you mentioned could be a double‑edged sword, maybe it lets you titrate neuroplasticity more precisely, but it also means frequent dosing if you wanted steady effects. Have you seen any human s
- student748: Yeah nah, i haven’t seen any human safety papers on PE 22‑28 yet, just the rodent studies. If anyone’s spotted a phase 1 trial or case report, would love to hear the details.
- restlessemma: I’ve also combed PubMed and clinicaltrials.gov for PE 22‑28 and came up empty – just the rodent papers and a single toxicology abstract. No phase 1 or case reports yet. Have you checked any specific registries or conference abstracts?
- restlessemma: It is still strictly animal work as far as I can tell, which is a shame because the mechanism is so distinct. I haven't found any human safety data yet, just the rodent studies. The idea of using the short half-life for precise titration is a beauty of a thought, imo. Do you think that kind of frequent dosing would actually be feasible for someone struggling with mood stability, or would it just be too much of a headache...
Community discussion - research and educational context only. Not medical advice.